Tickeron detected bullish Stock Pattern: Channel up GMRE on October 20, 2021, netting in a 6.31% gain over 2 weeks
A.I.dvisor at Tickeron, Inc Recommendation: Strong Buy SHARE 11/04/21 @RealEstateInvestmentTrusts#MissedOpportunity#TechnicalAnalysis#Bullish#ArtificialIntelligence#Pattern#Stocks#SmallCap#Russel2000
On October 19, 2021, A.I.dvisor detected a Channel up Pattern (Bullish) for Global Medical REIT (GMRE, $16.00). On October 20, 2021, A.I.dvisor confirmed the Bullish pattern, setting a target price of $17.02. 15 days later, on November 04, 2021, GMRE reached the target price resulting in a +6.31% for traders who took a long position in the stock.
FIND MORE STOCK PATTERNS: TRY FOR FREE
Current price $17.16 is above $16.31 the highest resistance line found by A.I. Throughout the month of 10/04/21 - 11/03/21, the price experienced a +15% Uptrend. During the week of 10/27/21 - 11/03/21, the stock enjoyed a +2% Uptrend growth.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for GMRE just turned positive on October 06, 2021. Looking at past instances where GMRE's MACD turned positive, the stock continued to rise in 35 of 50 cases over the following month. The odds of a continued upward trend are 70%.
GMRE moved above its 50-day Moving Average on October 06, 2021 date and that indicates a change from a downward trend to an upward trend.
The 10-day Moving Average for GMRE crossed bullishly above the 50-day moving average on October 13, 2021. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 59%.
Following a +1.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where GMRE advanced for three days, in 247 of 327 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 202 of 282 cases where GMRE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 72%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Indicator demonstrated that the ticker has stayed in the overbought zone for 19 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GMRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 53%.
GMRE broke above its upper Bollinger Band on October 20, 2021. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Tickeron has a positive outlook on this ticker and predicts a further increase by more than 4.00% within the next month with a likelihood of 75%. During the last month, the daily ratio of advancing to declining volumes was 2.98 to 1.
The Tickeron Profit vs. Risk Rating rating for this company is 23 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock better than average.
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.019) is normal, around the industry mean (3.350). P/E Ratio (113.636) is within average values for comparable stocks, (53.155). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (8.787). Dividend Yield (0.048) settles around the average of (0.049) among similar stocks. P/S Ratio (8.726) is also within normal values, averaging (9.689).
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. GMRE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 72 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
XRN sees MACD Histogram crosses below signal line
XRN saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 10, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 40 instances where the indicator turned negative. In 29 of the 40 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 73%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XRN as a result. In 50 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 62%.
XRN moved below its 50-day moving average on September 11, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
The Aroon Indicator for XRN entered a downward trend on August 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The 10-day moving average for XRN crossed bullishly above the 50-day moving average on August 24, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.
Following a +1.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where XRN advanced for three days, in 176 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
XRN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.099) is normal, around the industry mean (3.329). P/E Ratio (9.750) is within average values for comparable stocks, (49.356). XRN's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (4.353). XRN's Dividend Yield (0.158) is considerably higher than the industry average of (0.057). P/S Ratio (3.173) is also within normal values, averaging (6.065).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. XRN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 57 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 66 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the acquisition of purpose-built healthcare facilities and leasing of those properties to strong healthcare systems and physician groups
Industry PublishingBooksMagazines
Advertisement